ArticleHarm reduction journal2015
Orienting patients to greater opioid safety: models of community pharmacy-based naloxone.
Article in Harm reduction journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 1 synthesis or guideline pooled it, 112 citations in OpenAlex.
- Leveraging the role of community pharmacists in the prevention, surveillance, and treatment of opioid use disorders.Addiction science & clinical practice · 2019Pooled it
- Naloxone training programs in corporately-owned versus independently-owned Alabama community pharmacies: A pilot cross-sectional survey.Drug and alcohol dependence reports · 2025Article
- Evaluation of an emergency department-based approach to reduce subsequent opioid overdoses.Journal of the American College of Emergency Physicians open · 2024Article
- Investigating the complexity of naloxone distribution: Which policies matter for pharmacies and potential recipients.Journal of health economics · 2024Article
- Pilot study of a community pharmacist led program to treat hepatitis C virus among people who inject drugs.Drug and alcohol dependence reports · 2024Article
- Identifying Prescription-Opioid-Related Risks Using Prescription Drug Monitoring Programs' Algorithms and Clinical Screening Tools.Pharmacy (Basel, Switzerland) · 2023Article
- Article
- A longitudinal study of naloxone opioid overdose awareness and reversal training for first-year medical students: specific elements require reinforcement.Harm reduction journal · 2022Article
- Study protocol for the Respond to Prevent Study: a multi-state randomized controlled trial to improve provision of naloxone, buprenorphine and nonprescription syringes in community pharmacies.Substance abuse · 2022Article
- Naloxone's role in the national opioid crisis-past struggles, current efforts, and future opportunities.Translational research : the journal of laboratory and clinical medicine · 2021Review
- Community pharmacists' preparedness to intervene with concerns around prescription opioids: findings from a nationally representative survey.International journal of clinical pharmacy · 2021Article
- The Opioid-overdose Reduction Continuum of Care Approach (ORCCA): Evidence-based practices in the HEALing Communities Study.Drug and alcohol dependence · 2020Article
- Association between state Medicaid expansion status and naloxone prescription dispensing.Health services research · 2020Article
- Preliminary Investigation of Pharmacist-Delivered, Direct-to-Provider Interventions to Reduce Co-Prescribing of Opioids and Benzodiazepines among a Medicare Population.Pharmacy (Basel, Switzerland) · 2020Article
- Implementation of an Opioid Overdose and Naloxone Distribution Training in a Pharmacist Laboratory Course.American journal of pharmaceutical education · 2020Article
- Medication treatment for opioid use disorder and community pharmacy: Expanding care during a national epidemic and global pandemic.Substance abuse · 2020Article
- Evaluation of Bexar County community pharmacist attitudes toward harm reduction.The mental health clinician · 2019Article
- Will converting naloxone to over-the-counter status increase pharmacy sales?Health services research · 2019Article
- Pharmacist Services in the Opioid Crisis: Current Practices and Scope in the United States.Pharmacy (Basel, Switzerland) · 2019Article
- Beliefs Associated with Pharmacy-Based Naloxone: a Qualitative Study of Pharmacy-Based Naloxone Purchasers and People at Risk for Opioid Overdose.Journal of urban health : bulletin of the New York Academy of Medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 5 institutions in 1 country.
Funding
Abstract
The leading cause of adult injury death in the U.S.A. is drug overdose, the majority of which involves prescription opioid medications. Outside of the U.S.A., deaths by drug overdose are also on the rise, and overdose is a leading cause of death for drug users. Reducing overdose risk while maintaining access to prescription opioids when medically indicated requires careful consideration of how opioids are prescribed and dispensed, how patients use them, how they interact with other medications, and how they are safely stored. Pharmacists, highly trained professionals expert at detecting and managing medication errors and drug-drug interactions, safe dispensing, and patient counseling, are an under-utilized asset in addressing overdose in the U.S. and globally. Pharmacies provide a high-yield setting where patient and caregiver customers can access naloxone-an opioid antagonist that reverses opioid overdose-and overdose prevention counseling. This case study briefly describes and provides two US state-specific examples of innovative policy models of pharmacy-based naloxone, implemented to reduce overdose events and improve opioid safety: Collaborative Pharmacy Practice Agreements and Pharmacy Standing Orders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.